Is interferon-beta an alternative treatment for chronic hepatitis C?

World Journal of Gastroenterology

Volumn 12, Issue 17, 2006, Pages 2730-2736

  Moreno Otero, Ricardo ^a   Trapero Marugán, María ^a   Gómez Domínguez, Elena ^a   García Buey, Luisa ^a   Moreno Monteagudo, José A ^a  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

Author keywords

Hepatitis C; Hepatitis C virus; Interferon beta; Ribavirin

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; RIBAVIRIN;

CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FLU LIKE SYNDROME; FOLLOW UP; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INCIDENCE; INJECTION SITE REACTION; LIVER DYSFUNCTION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; PATIENT COMPLIANCE; PROTEINURIA; RANDOMIZATION; REVIEW; THROMBOCYTOPENIA; VIRUS LOAD;

EID: 33744474071     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v12.i17.2730     Document Type: Review

References (56)

1. CDC. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47: 1-39
2. Recommendations from the National Institutes of Health consensus development conference statement: management of hepatitis C: 2002. Hepatology 2002; 36: 1039
3. Medina J, Garcia-Buey L, Moreno-Monteagudo JA, Trapero-Marugan M, Moreno-Otero R. Combined antiviral options for the treatment of chronic hepatitis C. Antiviral Res 2003; 60: 135-143
4. Manns W, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-965
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D, Craxi A, Lin A, Hoffman J, Yu J. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-982
6. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Annu Rev Biochem 1987; 56: 727-777
7. Bocci V. Physicochemical and biologic properties of interferons and their potential uses in drug delivery systems. Crit Rev Ther Drug Carrier Syst 1992; 9: 91-133
8. Alam JJ. Interferon-beta treatment of human disease. Curr Opin Biotechnol 1995; 6: 688-691
9. Bertolotto A, Deisenhammer F, Gallo P, Solberg Sorensen P. Immunogenicity of interferon beta: differences among products. J Neurol 2004; 251 Suppl 2: II15-II24
10. Munafo A, Trinchard-Lugan II, Nguyen TX, Buraglio M. Comparative pharmacokinetics and pharmacodynamics of recombinant human interferon beta-1a after intramuscular and subcutaneous administration. Eur J Neurol 1998; 5: 187-193
11. Kiyosawa K, Sodeyama T, Nakano Y, Yoda H, Tanaka E, Hayata T, Tsuchiya K, Yousuf M, Furuta S. Treatment of chronic non-A non-B hepatitis with human interferon beta: a preliminary study. Antiviral Res 1989; 12: 151-161
12. Fesce E, Airoldi A, Mondazzi L, Maggi G, Gubertini G, Bernasconi G, Del Poggio P, Bozzetti F, Ideo G. Intramuscular beta interferon for chronic hepatitis C: is it worth trying? Ital J Gastroenterol Hepatol 1998; 30: 185-188
13. Shiratori Y, Perelson AS, Weinberger L, Imazeki F, Yokosuka O, Nakata R, Ihori M, Hirota K, Ono N, Kuroda H, Motojima T, Nishigaki M, Omata M. Different turnover rate of hepatitis C virus clearance by different treatment regimen using interferon-beta. J Hepatol 2000; 33: 313-322
14. Yoshioka K, Yano M, Hirofuji H, Arao M, Kusakabe A, Sameshima Y, Kuriki J, Kurokawa S, Murase K, Ishikawa T, Kakumu S. Randomized controlled trial of twice-a-day administration of natural interferon beta for chronic hepatitis C. Hepatol Res 2000; 18: 310-319
15. Lindsay KL. Therapy of hepatitis C: overview. Hepatology 1997; 26: 71S-77S
16. Kainuma M, Ogata N, Kogure T, Kohta K, Hattori N, Mitsuma T, Terasawa K. The efficacy of a herbal medicine (Mao-to) in combination with intravenous natural interferon-beta for patients with chronic hepatitis C, genotype 1b and high viral load: a pilot study. Phytomedicine 2002; 9: 365-372
17. Fukutomi T, Fukutomi M, Iwao M, Watanabe H, Tanabe Y, Hiroshige K, Kinukawa N, Nakamuta M, Nawata H. Predictors of the efficacy of intravenous natural interferon-beta treatment in chronic hepatitis C. Med Sci Monit 2000; 6: 692-698
18. Kurosaki M, Enomoto N, Murakami T, Sakuma I, Asahina Y, Yamamoto C, Ikeda T, Tozuka S, Izumi N, Marumo F, Sato C. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy. Hepatology 1997; 25: 750-753
19. Alberti A, Chemello L, Bonetti P, Casarin C, Diodati G, Cavalletto L, Cavalletto D, Frezza M, Donada C, Belussi F. Treatment with interferon(s) of community-acquired chronic hepatitis and cirrhosis type C. The TVVH Study Group. J Hepatol 1993; 17 Suppl 3: S123-126
20. Kaito M, Yasui-Kawamura N, Iwasa M, Kobayashi Y, Nakagawa N, Fujita N, Ikoma J, Gabazza EC, Watanabe S, Adachi Y. Twice-a-day versus once-a-day interferon-beta therapy in chronic hepatitis C. Hepatogastroenterology 2003; 50: 775-778
21. Shiratori Y, Nakata R, Shimizu N, Katada H, Hisamitsu S, Yasuda E, Matsumura M, Narita T, Kawada K, Omata M. High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group. Dig Dis Sci 2000; 45: 2414-2421
22. Mochizuki K, Kagawa T, Takashimizu S, Kawazoe K, Kojima S, Nagata N, Nakano A, Nishizaki Y, Shiraishi Y, Itakura M, Watanabe N, Mine T, Matsuzaki S. Effect of in vitro interferon-beta administration on hepatitis C virus in peripheral blood mononuclear cells as a predictive marker of clinical response to interferon treatment for chronic hepatitis C. World J Gastroenterol 2004; 10: 733-736
23. Kakizaki S, Takagi H, Yamada T, Ichikawa T, Abe T, Sohara N, Kosone T, Kaneko M, Takezawa J, Takayama H, Nagamine T, Mori M. Evaluation of twice-daily administration of interferon-beta for chronic hepatitis C. J Viral Hepat 1999; 6: 315-319
24. Suzuki F, Chayama K, Tsubota A, Akuta N, Someya T, Kobayashi M, Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kumada H. Twice-daily administration of interferon-beta for chronic hepatitis C is not superior to a once-daily regimen. J Gastroenterol 2001; 36: 242-247
25. Enomoto M, Nishiguchi S, Tanaka M, Fukuda K, Ueda T, Tamori A, Habu D, Takeda T, Shiomi S, Yano Y, Otani S. Dynamics of hepatitis C virus monitored by real-time quantitative polymerase chain reaction during first 2 weeks of IFN-beta treatment are predictive of long-term therapeutic response. J Interferon Cytokine Res 2002; 22: 389-395
26. Habersetzer F, Boyer N, Marcellin P, Bailly F, Ahmed SN, Alam J, Benhamou JP, Trepo C. A pilot study of recombinant interferon beta-1a for the treatment of chronic hepatitis C. Liver 2000; 20: 437-441
27. Andrade RJ, Garcia-Escano MD, Valdivielso P, Alcantara R, Sanchez-Chaparro MA, Gonzalez-Santos P. Effects of interferon-beta on plasma lipid and lipoprotein composition and post-heparin lipase activities in patients with chronic hepatitis C. Aliment Pharmacol Ther 2000; 14: 929-935
28. Castro A, Carballo E, Dominguez A, Diago M, Suarez D, Quiroga JA, Carreno V. Tolerance and efficacy of subcutaneous interferon-beta administered for treatment of chronic hepatitis C. J Interferon Cytokine Res 1997; 17: 65-67
29. Castro A, Suarez D, Inglada L, Carballo E, Dominguez A, Diago M, Such J, Del Olmo JA, Perez-Mota A, Pedreira J, Quiroga JA, Carreno V. Multicenter randomized, controlled study of intramuscular administration of interferon-beta for the treatment of chronic hepatitis C. J Interferon Cytokine Res 1997; 17: 27-30
30. Villa E, Trande P, Grottola A, Buttafoco P, Rebecchi AM, Stroffolini T, Callea F, Merighi A, Camellini L, Zoboli P, Cosenza R, Miglioli L, Loria P, Iori R, Carulli N, Manenti F. Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus. A prospective, double-blind, randomized study. Dig Dis Sci 1996; 41: 1241-1247
31. Kakumu S, Yoshioka K, Wakita T, Ishikawa T, Takayanagi M, Higashi Y. A pilot study of ribavirin and interferon beta for the treatment of chronic hepatitis C. Gastroenterology 1993; 105: 507-512
32. Perez R, Pravia R, Artimez ML, Giganto F, Rodriguez M, Lombrana JL, Rodrigo L. Clinical efficacy of intramuscular human interferon-beta vs interferon-alpha 2b for the treatment of chronic hepatitis C. J Viral Hepat 1995; 2: 103-106
33. Bernardinello E, Cavalletto L, Chemello L, Mezzocolli I, Donada C, Benvegnu L, Merkel C, Gatta A, Alberti A. Long-term clinical outcome after beta-interferon therapy in cirrhotic patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999; 46: 3216-3199
34. Frosi A, Sgorbati C, Bestetti B, Lodeville D, Vezzoli S, Vezzoli F. Interferon-α and -β in chronic hepatitis C: efficacy and tolerability. Clin Drug Invest 1995; 9: 226-231
35. Pellicano R, Craxi A, Almasio PL, Valenza M, Venezia G, Alberti A, Boccato S, Demelia L, Sorbello O, Picciotto A, Torre F, Ideo G, Cattaneo C, Berrutti M, Rizzetto M. Interferon beta-1a alone or in combination with ribavirin: a randomized trial to compare efficacy and safety in chronic hepatitis C. World J Gastroenterol 2005; 11: 4484-4489
36. Nakamura H, Uyama H, Enomoto H, Kishima Y, Yamamoto M, Yoshida K, Okuda Y, Hirotani T, Kuroda T, Ito H, Matsuda M, Terabayashi M, Noguchi S. The combination therapy of interferon and amantadine hydrochloride for patients with chronic hepatitis C. Hepatogastroenterology 2003; 50: 222-226
37. Nakamura H, Ogawa H, Kuroda T, Yamamoto M, Enomoto H, Kishima Y, Yoshida K, Ito H, Matsuda M, Noguchi S. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus. Hepatogastroenterology 2002; 49: 1373-1376
38. Asahina Y, Izumi N, Uchihara M, Noguchi O, Nishimura Y, Inoue K, Ueda K, Tsuchiya K, Hamano K, Itakura J, Miyake S. Interferon-stimulated gene expression and hepatitis C viral dynamics during different interferon regimens. J Hepatol 2003; 39: 421-427
39. Fukutomi T, Nakamuta M, Fukutomi M, Iwao M, Watanabe H, Hiroshige K, Tanabe Y, Nawata H. Decline of hepatitis C virus load in serum during the first 24 h after administration of interferon-beta as a predictor of the efficacy of therapy. J Hepatol 2001; 34: 100-107
40. Pellicano R, Palmas F, Cariti G, Tappero G, Boero M, Tabone M, Suriani R, Pontisso P, Pitaro M, Rizzetto M. Re-treatment with interferon-beta of patients with chronic hepatitis C virus infection. Eur J Gastroenterol Hepatol 2002; 14: 1377-1382
41. Asahina Y, Izumi N, Uchihara M, Noguchi O, Tsuchiya K, Hamano K, Kanazawa N, Itakura J, Miyake S, Sakai T. A potent antiviral effect on hepatitis C viral dynamics in serum and peripheral blood mononuclear cells during combination therapy with high-dose daily interferon alfa plus ribavirin and intravenous twice-daily treatment with interferon beta. Hepatology 2001; 34: 377-384
42. Barbaro G, Di Lorenzo G, Soldini M, Giancaspro G, Pellicelli A, Grisorio B, Barbarini G. Intravenous recombinant interferon-beta versus interferon-alpha-2b and ribavirin in combination for short-term treatment of chronic hepatitis C patients not responding to interferon-alpha. Multicenter Interferon Beta Italian Group Investigators. Scand J Gastroenterol 1999; 34: 928-933
43. Mazzoran L, Grassi G, Giacca M, Gerini U, Baracetti S, Fanni-Canelles M, Zorat F, Pozzato G. Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon. Ital J Gastroenterol Hepatol 1997; 29: 338-3342
44. Montalto G, Tripi S, Cartabellotta A, Fulco M, Soresi M, Di Gaetano G, Carroccio A, Levrero M. Intravenous natural beta-interferon in white patients with chronic hepatitis C who are nonresponders to alpha-interferon. Am J Gastroenterol 1998; 93: 950-953
45. Oketani M, Higashi T, Yamasaki N, Shinmyozu K, Osame M, Arima T. Complete response to twice-a-day interferon-beta with standard interferon-alpha therapy in acute hepatitis C after a needle-stick. J Clin Gastroenterol 1999; 28: 49-51
46. Furusyo N, Hayashi J, Ohmiya M, Sawayama Y, Kawakami Y, Ariyama I, Kinukawa N, Kashiwagi S. Differences between interferon-alpha and -beta treatment for patients with chronic hepatitis C virus infection. Dig Dis Sci 1999; 44: 608-617
47. Gattoni A, Cecere A, Caiazzo R, Romano C. [Hepatitis C] Clin Ter 1996; 147: 413-438
48. Cheng PN, Marcellin P, Bacon B, Farrell G, Parsons I, Wee T, Chang TT. Racial differences in responses to interferon-beta-1a in chronic hepatitis C unresponsive to interferon-alpha: a better response in Chinese patients. J Viral Hepat 2004; 11: 418-426
49. Vezzoli M, Girola S, Fossati G, Mazzucchelli I, Gritti D, Mazzone A. beta-Interferon therapy of chronic hepatitis HCV+, 1b genotype. Recenti Prog Med 1998; 89: 235-240
50. Nomura H, Sou S, Nagahama T, Hayashi J, Kashiwagi S, Ishibashi H. Efficacy of early retreatment with interferon beta for relapse in patients with genotype Ib chronic hepatitis C. Hepatol Res 2004; 28: 36-40
51. Uyama H, Enomoto H, Kishima Y, Yamamoto M, Yoshida K, Okuda Y, Hirotani T, Kuroda T, Ito H, Matsuda M, Terabayashi M, Noguchi S, Kawase I, Nakamura H. A pilot study of combination therapy with initial high-dose interferon and amantadine hydrochloride for patients with chronic hepatitis C with the genotype 1b virus. Hepatogastroenterology 2003; 50: 2112-2116
52. Ebinuma H, Saito H, Tada S, Masuda T, Kamiya T, Nishida J, Yoshioka M, Ishii H. Additive therapeutic effects of the liver extract preparation mixture adelavin-9 on interferon-beta treatment for chronic hepatitis C. Hepatogastroenterology 2004; 51: 1109-1114
53. Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Tada M, Ito Y, Ohto M. Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 1991; 338: 914-915
54. Takano S, Satomura Y, Omata M. Effects of interferon beta on non-A, non-B acute hepatitis: a prospective, randomized, controlled-dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology 1994; 107: 805-811
55. Munoz R, Castellano G, Fernandez I, Alvarez MV, Manzano ML, Marcos MS, Cuenca B, Solis-Herruzo JA. A pilot study of beta-interferon for treatment of patients with chronic hepatitis B who failed to respond to alpha-interferon. J Hepatol 2002; 37: 655-659
56. Festi D, Sandri L, Mazzella G, Roda E, Sacco T, Staniscia T, Capodicasa S, Vestito A, Colecchia A. Safety of interferon beta treatment for chronic HCV hepatitis. World J Gastroenterol 2004; 10: 12-16